Novo Nordisk Partners with OpenAI to Integrate AI Across Operations
Novo Nordisk A/S (NYSE:NVO) has announced a strategic partnership with OpenAI to integrate artificial intelligence into its operations, aiming to enhance drug discovery, reduce time-to-market for new medicines, and improve productivity. The collaboration includes AI training for employees and pilot programs in R&D, manufacturing, and commercial operations, with full integration planned by year-end. The partnership is not expected to reduce the workforce but to increase productivity.
Tickers: $NVO
Topics: AI integration artificial intelligence drug development healthcare partnerships